TScan Therapeutics Inc (TCRX)
9.03
+0.13
(+1.46%)
USD |
NASDAQ |
May 20, 10:17
TScan Therapeutics Total Assets (Quarterly): 240.83M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 240.83M |
| December 31, 2023 | 272.15M |
| September 30, 2023 | 291.38M |
| June 30, 2023 | 316.92M |
| March 31, 2023 | 173.58M |
| December 31, 2022 | 199.09M |
| September 30, 2022 | 165.45M |
| Date | Value |
|---|---|
| June 30, 2022 | 152.42M |
| March 31, 2022 | 168.20M |
| December 31, 2021 | 188.11M |
| September 30, 2021 | 204.89M |
| June 30, 2021 | 130.01M |
| March 31, 2021 | 140.94M |
| December 31, 2020 | 49.74M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
49.74M
Minimum
Dec 2020
316.92M
Maximum
Jun 2023
192.41M
Average
180.84M
Median
Total Assets (Quarterly) Benchmarks
| AnaptysBio Inc | 405.84M |
| CEL-SCI Corp | 30.05M |
| AIM ImmunoTech Inc | 19.38M |
| IGC Pharma Inc | 11.26M |
| NovaBay Pharmaceuticals Inc | 5.357M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 117.86M |
| Shareholders Equity (Quarterly) | 122.97M |
| Debt to Equity Ratio | 0.246 |
| Current Ratio | 5.233 |
| Net Debt Paydown Yield | -0.05% |